The Goldman Sachs Group Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S (NASDAQ:ASND) had its target price upped by The Goldman Sachs Group from $200.00 to $225.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other analysts also recently issued reports on ASND. Stifel Nicolaus raised their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Wedbush reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. UBS Group began coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 target price for the company. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Oppenheimer cut their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research note on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $193.43.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $144.08 on Thursday. The business has a fifty day moving average price of $132.41 and a 200 day moving average price of $132.35. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $161.00. The company has a market cap of $8.74 billion, a P/E ratio of -17.83 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, sell-side analysts predict that Ascendis Pharma A/S will post -7.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of ASND. T. Rowe Price Investment Management Inc. boosted its holdings in Ascendis Pharma A/S by 54.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company’s stock valued at $375,226,000 after acquiring an additional 960,504 shares during the period. Capital International Investors boosted its holdings in Ascendis Pharma A/S by 35.7% during the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock valued at $394,183,000 after acquiring an additional 753,859 shares during the period. Groupama Asset Managment purchased a new position in Ascendis Pharma A/S during the 3rd quarter valued at about $60,000. RA Capital Management L.P. boosted its holdings in Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock valued at $1,392,221,000 after acquiring an additional 402,316 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.